

Rita Spilka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8698338/publications.pdf>

Version: 2024-02-01

10
papers

288
citations

1478280

6
h-index

1372474

10
g-index

10
all docs

10
docs citations

10
times ranked

528
citing authors

#	ARTICLE	IF	CITATIONS
1	Promoter Methylation of Selected Genes in Non-Small-Cell Lung Cancer Patients and Cell Lines. International Journal of Molecular Sciences, 2020, 21, 4595.	1.8	9
2	The Relevance of Gender in Tumor-Influencing Epigenetic Traits. Epigenomes, 2019, 3, 6.	0.8	3
3	Current Coverage of the mTOR Pathway by Next-Generation Sequencing Oncology Panels. International Journal of Molecular Sciences, 2019, 20, 690.	1.8	4
4	Expression profile of translation initiation factor eIF2B5 in diffuse large B-cell lymphoma and its correlation to clinical outcome. Blood Cancer Journal, 2018, 8, 79.	2.8	4
5	ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers, 2017, 9, 33.	1.7	25
6	Organotypic three-dimensional cancer cell cultures mirror drug responses <i>in vivo</i> : lessons learned from the inhibition of EGFR signaling. Oncotarget, 2017, 8, 107423-107440.	0.8	36
7	The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomarker Research, 2016, 4, 8.	2.8	6
8	eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cellular Oncology (Dordrecht), 2014, 37, 253-267.	2.1	48
9	Eukaryotic translation initiation factors in cancer development and progression. Cancer Letters, 2013, 340, 9-21.	3.2	130
10	Overexpression of eIF3a in Squamous Cell Carcinoma of the Oral Cavity and Its Putative Relation to Chemotherapy Response. Journal of Oncology, 2012, 2012, 1-9.	0.6	23